Application of IL-12 in preparation of medicine for treating T-ALL
By constructing a non-irradiated T-ALL mouse model and using IL-12 treatment, the problems of low cure rate and large toxic and side effects of acute T lymphocytic leukemia treatment were solved, and the effect of significantly improving survival rate and prolonging survival was achieved. New treatment ideas and clinical application prospects have been developed.
Patent Information
- Application Number
- CN202411417365.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-11
- Publication Date
- 2024-12-06
AI Technical Summary
In the prior art, the cure rate of acute T lymphocyte leukemia is low and has great toxic side effects, which cannot effectively inhibit cancer cells and improve the body's immune ability.
IL-12 is used to prepare drugs for treating acute T lymphocytic leukemia, and the therapeutic effect of IL-12 is verified by constructing a non-irradiated T-ALL mouse model, and a composition containing IL-12 and cells expressing IL-12 are provided. or genetic material is used for adjuvant therapy.
After IL-12 treatment, mice can significantly resist the viability of T-ALL cells. The survival period of surviving mice is close to that of normal mice. The cured bone marrow cells can prolong the survival time of leukemia mice, providing New treatment ideas and clinical application prospects.
Smart Images

Figure CN119074896A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of biomedicine, and in particular, to the use of IL-12 in preparing a drug for treating acute T-lymphocytic leukemia. Background Art
[0002] Interleukin-12 (IL-12) is a cytokine with a wide range of biological activities, mainly produced by activated inflammatory cells. Studies have found that IL-12 has the ability to inhibit the progression of solid tumors, which is consistent with the results obtained in some preclinical studies. Meeran SM and Liu J et al. found that IL-12 dysfunction would aggravate the carcinogenic effect and tumorigenicity of chemical agents, while Airoldi I and Zhao B et al. found that the degree of inhibition of IL-12 expression was positively correlated with the susceptibility of glioblastoma. These studies all show that IL-12 is closely related to the progression of tumors. Gately et al. found that IL-12 has an inhibitory effect on lung metastasis caused by melanoma cells (B16F10), liver metastasis caused by reticular cell sarcoma cells (M5076), and renal cell adenocarcinoma. The experimental results of Nastala et al. showed that IL-12 has an inhibitory effect on colon adenocarcinoma and sarcoma caused by MCA-105 and MC-38 tumor cells implanted in the peritoneal cavity of mice. Mu J et al. found that IL-12 also has an inhibitory effect on virus-induced CSA1M fibrosarcoma, radiation-induced OV-HM ovarian cancer, and chemically induced MCH-1-A1 fibrosarcoma. Verbik et al. implanted BALB / c mice with 1×10 3 IL-12 was given by intraperitoneal injection 24 hours after the inoculation of RAW117-H10 lymphoma cells. The results showed that IL-12 could effectively improve the overall survival rate of lymphoma mice and effectively inhibit tumor metastasis. O'Donnell et al. used MB49 tumor cells to construct a bladder cancer tumor model and found that IL-12 could improve the survival rate of bladder cancer mice and produce immune protection. Boggio et al. used transgenic BALB / c mice (BALB-neu T mice) that overexpressed the HER-2 / neu oncogene and FVB mice carrying the HER-2 / neu oncogene to study the effect of IL-12 on breast cancer. The results showed that IL-12 could effectively inhibit tumor proliferation.
[0003] Acute T-lymphoblastic leukemia (T-ALL) is a malignant disease of the blood system that affects lymphocytes, mainly caused by abnormal differentiation and proliferation of T lymphocytes. Research on the treatment of acute T-lymphoblastic leukemia still focuses on the exploration of inhibition and killing of tumor cells, hoping to curb the development of cancer cells by increasing the dose of chemotherapy drugs. However, clinical and scientific research data suggest that relying solely on high-dose chemotherapy to achieve complete remission is not the best means, and about 15% to 20% of young patients cannot produce a sustained response to chemotherapy. In addition, even after complete remission, there are still residual leukemia cells to varying degrees, and chemotherapy has greater side effects and marginal effects. Therefore, inhibiting cancer cells and improving the body's immune ability and the competitiveness of normal cells at the same time will more effectively prolong the patient's survival. In view of the problems existing in the above prior art, continue to find a new solution. Summary of the invention
[0004] Technical issues solved:
[0005] One aspect of the present disclosure is to provide a new solution to the defects of the prior art treatments for acute T-lymphocytic leukemia, such as low cure rate and significant toxic side effects.
[0006] Technical solution:
[0007] Use of IL-12 in preparing medicine for treating acute T lymphocytic leukemia.
[0008] The mouse models used to simulate T-ALL in the prior art are immunodeficient or immunocompromised mice, which cannot effectively demonstrate the therapeutic effect of IL-12. Therefore, the inventors constructed a non-irradiated T-ALL mouse model that can better simulate the clinical T-ALL pathogenesis, and used this model to verify the therapeutic effect of IL-12 on T-ALL, and the results are more clinically instructive.
[0009] Furthermore, another aspect of the present disclosure provides the use of IL-12 in preparing a drug for adjuvant treatment of acute T lymphocytic leukemia.
[0010] Furthermore, another aspect of the present disclosure is to provide use of a composition comprising IL-12 in the preparation of a medicament for treating acute T-lymphocytic leukemia.
[0011] Furthermore, another aspect of the present disclosure is to provide use of a composition comprising IL-12 in the preparation of a medicament for the adjuvant treatment of acute T-lymphocytic leukemia.
[0012] Furthermore, another aspect of the present disclosure provides the use of cells or genetic materials expressing IL-12 in the preparation of drugs for treating acute T lymphocytic leukemia.
[0013] Furthermore, another aspect of the present disclosure provides the use of cells or genetic materials expressing IL-12 in the preparation of drugs for the adjuvant treatment of acute T-lymphocytic leukemia.
[0014] Based on the technical solution disclosed in the present invention, the inventors further found that the mice that survived the IL-12 treatment had a very obvious ability to resist the survival of T-ALL cells, and T-ALL would not develop even if the T-ALL cells were transplanted again for the second or third time at 10 times the amount. And the total survival period of the surviving mice was close to that of normal mice. The bone marrow cells of the cured mice were collected and used to treat other T-ALL mice, which could also appropriately prolong the survival time of the leukemia mice. Therefore, further, another aspect of the present disclosure is to provide the use of cells in the preparation of drugs for the treatment or adjuvant treatment of acute T lymphocytic leukemia, wherein the cells are bone marrow cells of humans or experimental animals that have been cured by IL-12 treatment.
[0015] Beneficial effects:
[0016] The present invention discovered and used a non-irradiated T-ALL mouse model to verify the therapeutic effect of IL-12 on acute T lymphocytic leukemia, providing a new idea and experimental basis for the clinical treatment of T-ALL and having a good application prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Result diagrams of pathological changes of different organs in the embodiments of the present disclosure;
[0018] Figure 2 This is a graph showing the results of a routine blood test in peripheral blood in the embodiments of the present disclosure;
[0019] Figure 3 This is a result diagram of the competitive proliferation process of leukemia cells in the embodiment of the present disclosure;
[0020] Figure 4 This is a result diagram of the proliferation of leukemia cells in the bone marrow after transplantation in the disclosed embodiment;
[0021] Figure 5 This is a result diagram of the changes of leukemia cells in different organs after transplantation in the embodiment of the present disclosure;
[0022] Figure 6 This is a graph showing the therapeutic ability of different concentrations of IL-12 in the embodiments of the present disclosure;
[0023] Figure 7This is a graph showing the results of the pathogenicity of the secondary transplanted leukemia cells in the embodiments of the present disclosure;
[0024] Figure 8 This is a graph showing the pathogenicity results of three transplantations of leukemia cells in the disclosed embodiment;
[0025] Fig. 9 This is a graph showing the results of the pathogenicity of transplanted extreme leukemia cells in the disclosed embodiment;
[0026] Fig.10 This is a graph showing the total survival time of leukemia mice after treatment in the disclosed embodiments. DETAILED DESCRIPTION
[0027] The present invention discloses the use of IL-12 in the preparation of a drug for treating acute T lymphocytic leukemia. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly pointed out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention, and relevant personnel can obviously modify or appropriately change and combine the contents described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0028] In the present invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Unless otherwise expressly stated, throughout the specification and claims, the term "include" or its transformations such as "include" or "include" etc. will be understood to include the elements or components stated, without excluding other elements or other components. The term "one (a)" ("a", "an" and "the") includes plural indicators. The term "multiple (multiple)" refers to two (kinds) or more (kinds). The terms "such as", "for example" etc. are intended to refer to exemplary embodiments, and are not intended to limit the scope of the present disclosure.
[0029] In the present disclosure, when a range of values is provided, it should be understood that the endpoints are included in the range and each intervening value between the upper and lower limits of the range and any other specified value or intervening value in the specified range and any value in the smaller range between the specified values are included unless the context clearly dictates otherwise.
[0030] In this disclosure, the term "about" generally refers to variations within a range of 0.5%-10% above or below a specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.
[0031] In the present disclosure, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. The definition of common terms in molecular biology can be found in Lewin's GENES, Twelfth Edition, Jocelyn E. Krebs, Elliott S. Goldstein, Stephen T. Kilpatrick, Publisher: Jones & Bartlett Learning. The definition of common terms in biochemistry can be found in Lehninger Principles of Biochemistry, Eighth Edition, David L. Nelson, Michael M. Cox, Publisher: WH Freeman. The definition of common terms in cell biology can be found in Molecular Biology of the Cell, Sixth Edition, Bruce Alberts, Alexander Johnson, Julian Lewis, David Morgan, Martin Raff, Keith Roberts, Peter Walter, Publisher: Garland Science. The definition of common terms in genetics can be found in Genetics: Analysis of Genes and Genomes, Eighth Edition, Daniel L. Hartl, Maryellen Ruvolo, Publisher: Jones & Bartlett Learning.
[0032] Unless otherwise specified, the experimental techniques herein employ conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which can be found in standard books such as the following: Molecular Cloning: A Laboratory Manual; Cell Biology: A Laboratory Handbook, etc.
[0033] the term:
[0034] The term "treatment" as used in this disclosure refers to the process of intervening or changing a specific health state, the purpose of which is to eliminate the cause, relieve symptoms, improve the condition or prevent further development of the disease through means such as medication, surgery, physical therapy, psychotherapy, etc. This process involves multiple links such as the assessment of the patient's condition, the formulation of a treatment plan, the implementation of treatment measures, and the evaluation of treatment effects. In this disclosure, the term treatment generally refers to drug therapy. In this disclosure, the subject of the treatment can be a human or other mammal, examples of which include mice, rabbits, dogs, monkeys, cows, horses, sheep, etc.
[0035] The term "adjuvant therapy" used in this disclosure generally refers to a series of treatment measures given after or simultaneously with the primary treatment (such as surgery, radiotherapy or chemotherapy, etc.). These measures are often intended to eliminate possible residual lesions in the body, reduce the risk of disease recurrence or spread to other parts, and alleviate side effects during treatment, improving the patient's quality of life and tolerance.
[0036] The term "composition" used in the present disclosure can be interchanged with "pharmaceutical composition". In some embodiments of the present disclosure, in addition to an effective dose of IL-12, the composition may also contain other drugs for the treatment or adjuvant treatment of T-ALL. For example, chemotherapeutic drugs (e.g., cyclophosphamide, vincristine, doxorubicin, nelarabine, etc.), immunotherapy drugs (e.g., belintoxan, etc.), molecular targeted drugs (e.g., ibrutinib, etc.), supportive therapy drugs, etc. IL-12 and other components in the composition can coexist in appropriate doses and forms.
[0037] The term "cell" used in the present disclosure may refer to a wild-type cell or an engineered cell. The cell may be homologous or heterologous. The cell may express an IL-12 molecule.
[0038] The term "genetic material" used in the present disclosure refers to a substance used to store genetic information in the nucleus or mitochondria of cells of an organism. Examples of genetic material include, but are not limited to, double-stranded or single-stranded DNA, cDNA, RNA, and mRNA.
[0039] The term "cure" as used in this disclosure means recovery after treatment, or restoration to good health, or complete remission of the disease or symptoms, and no recurrence of the disease or a low probability of recurrence within a period of time after treatment. For experimental animals, it also means that they will not develop the disease like the control group under the same modeling conditions.
[0040] Example:
[0041] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with specific embodiments.
[0042] Example 1: Construction of mouse leukemia model
[0043] 1. Mouse HSC / HPC (Lin - ) Cell preparation and pre-stimulation
[0044] Preparation of bone marrow cell suspension:
[0045] 1) The donor mice (B6.SJL) were killed by cervical dislocation, and the limb bones and iliac bones of the mice were obtained by soaking in 75% ethanol solution for 1 minute;
[0046] 2) After removing the muscle, use a 1 mL syringe to repeatedly flush the bone marrow cavity from the limb bones and both ends of the ilium, and use a pipette to repeatedly blow and beat to prepare a single cell suspension. Filter with a 400-mesh filter to remove muscle and bone tissue fragments and place on ice for later use;
[0047] 3) After centrifugation (300 g × 10 min), remove the supernatant, wash once with PBE and count;
[0048] 4) According to every 10 7 After the cells were resuspended in 40 μL PBE buffer, pre-mixed biotin-conjugated antibodies of each series (Lineage cocktails) were added and incubated on ice for 10 min;
[0049] 5) According to every 10 7 The cells were then added with 30 μL PBE buffer, avidin-conjugated micromagnetic beads (Streptavidin Microbeads), and incubated on ice for 15 min;
[0050] 6) Every 10 7 Wash the cells once with 1 mL of PBE buffer and resuspend every 108 cells in 500 μL of PBE; add 1 mL of PBE buffer to rinse the Lineage magnetic column and let the liquid flow down naturally by gravity;
[0051] 7) Add the cell suspension to the rinsed magnetic column, let the liquid flow out by gravity, then rinse with 3 mL PBE buffer 3 times, let the liquid flow out naturally by gravity, and collect each series of antibody negative cells (Lineage negative, Lin - ) and count.
[0052] Mouse Lin - Cell culture and pre-stimulation:
[0053] 1) The cells were cultured in 24-well plates using IMDM medium containing 15% FBS, with a cell density of 5×10 5 / mL;
[0054] 2) Add cytokines for pre-stimulation, mouse SCF (50 ng / mL), Flt3-L (25 ng / mL), TPO (25 ng / mL);
[0055] 3) Place the culture plate in a 37°C 5% CO2 cell culture incubator and continue culturing.
[0056] 2. Gene transfer
[0057] 1) Mouse bone marrow Lin - After the cells were pre-stimulated with cytokines for 6 hours, they were collected for gene transfer.
[0058] 2) Centrifuge at 300 g for 10 minutes at 4°C.
[0059] 3) Resuspend the cells (80% viral supernatant + 20% fresh IMDM medium, the latter containing 15% FBS, 50ng / mL SCF, 25ng / mL Flt3-L, 25ng / mL TPO and polybrene 6μg / mL), the cell concentration is 5×10 5 / mL.
[0060] 4) Inoculate cells in a 24-well plate, 2 mL per well (the 24-well plate was pretreated with Retronectin, 10 μg Retronectin per well, 200 μL Retronectin with a protein concentration of 50 μg / mL, and the operation was carried out according to the product instructions).
[0061] 5) Place the culture plate in a 37°C 5% CO2 cell culture incubator and continue culturing for 12-14 hours, then discard the viral supernatant.
[0062] 6) Add fresh IMDM culture medium containing 15% FBS, 50 ng / mL SCF, 25 ng / mL Flt3-L, and 25 ng / mL TPO to the culture plate, and place the culture plate in a 37° C. 5% CO 2 cell culture incubator for further culturing for 12-14 hours.
[0063] 7) The cell culture medium in the culture wells was discarded and a second virus infection was performed (80% virus supernatant + 20% fresh IMDM medium, the latter containing 15% FBS, 50 ng / mL SCF, 25 ng / mL Flt3-L, 25 ng / mL TPO and 6 μg / mL polybrene).
[0064] 8) Place the culture plate in a 37°C 5% CO2 cell culture incubator and continue culturing for 12-14 hours, then discard the viral supernatant.
[0065] 9) Add fresh IMDM culture medium containing 15% FBS, 50 ng / mL SCF, 25 ng / mL Flt3-L, and 25 ng / mL TPO to the culture plate, and place the culture plate in a 37° C. 5% CO 2 cell culture incubator for further culturing for 12-14 hours.
[0066] 10) Collect cells (After aspirating the cell suspension, add 0.5 mL of cell separation solution to each well to separate and collect cells adhered to Retronctin, and collect cells by centrifugation at 1500 g for 10 minutes. The collected cells are used for subsequent experiments.
[0067] 3. Determination of gene transfer efficiency
[0068] Reversal virus supernatant infected mouse bone marrow HSC / HPC (Lin - ) cells, the cells were collected 72 hours after transfection, and the GFP positive ratio was detected by flow cytometry to obtain the gene transfer efficiency (%).
[0069] 4. Establishment of T-ALL model in non-irradiated mice
[0070] Bone marrow single cell suspension of B6.SJL mice (6-8 weeks, CD45.1) was prepared according to conventional methods, and cells were sorted by magnetic bead sorting method in 2 above, and then the bone marrow HSC / HPC (Lin - ) cells, and the infected cells were cultured in 24-well plates at a cell concentration of 5×10 5 / mL, the cytokine dosage and culture method were the same as before. After 2 days of in vitro culture, cells were collected and GFP was determined by flow cytometry + Cell ratio.
[0071] Recipient mice (B6.SJL, 6-8 weeks, female) were subjected to total body irradiation (TBI) before transplantation. The radiation source was 137Cs, the single dose was 9.5Gy, the dose rate was 80.6cGy, and it was divided into two irradiations of 4.75Gy each time, with an interval of at least 2 hours. After the irradiation, the cells were transplanted after waiting for at least 4 hours. The number of transplanted cells per mouse was about 5×10 5, one mouse was transplanted with infected cells in each well. The mice developed leukemia and died after about 50-70 days. Flow cytometry showed that the leukemia in the mice was T-ALL, and the leukemia cells were recorded as P0 generation. P0 generation leukemia cells were transplanted into non-irradiated B6.SJL mice (6-8 weeks, female). The mice developed leukemia and died after about 40-50 days. Flow cytometry showed that the mice still developed T-ALL leukemia, and the leukemia cells were recorded as P1 generation.
[0072] Construction of non-irradiated leukemia model: Each mouse (C57BL / 6J, CD45.2, 6-8 weeks, female) was transplanted with 1×10 ICN1-GFPCD45.1 P1 leukemia cells. 6 / Only.
[0073] 5. Model verification:
[0074] The tissues and organs of the diseased mice obtained above were collected: liver, spleen, lymph nodes, lungs, kidneys, thymus, and femur for pathological examination. The test results showed that tumor cells accumulated in different organs of the diseased mice (see Figure 1 ). The routine blood test in peripheral blood showed that with the progression of leukemia, WBC increased significantly on the 10th day after transplantation (t=3.392, P<0.01), and increased significantly on the 14th day after transplantation (14Day: t=8.026, P<0.001; 17Day: 5.804, P<0.001). However, there was no significant change in red blood cells, and platelets began to decrease significantly on the 10th day after transplantation (see Figure 2 Further analysis of the changes in white blood cells in the bone marrow of leukemia mice showed that as the disease progressed, the number of normal white blood cells continued to decrease, while the number of leukemia cells increased sharply (see Figure 3 ). Through counting and analysis, it was found that the number of white blood cells in the bone marrow continued to increase. The number of normal white blood cells gradually increased, but the number of leukemia cells increased more dramatically (see Figure 4 ). The results of routine blood tests in peripheral blood indicated that in the early stage of leukemia (≤5D), the accumulation of leukemia cells in the body was not obvious. Further analysis of the accumulation of leukemia cells in different tissues and organs of mice after leukemia cell transplantation revealed that after transplantation, leukemia cells gradually transferred from peripheral blood, lungs, and liver to spleen (see Figure 5 ). The above results prove that the constructed non-irradiation-induced / non-drug-induced / non-immune-deficiency mouse leukemia model can better reflect the pathogenesis of leukemia, how leukemia cells invade, inhibit and eventually destroy the body's normal defense system, and can more realistically reflect the development of leukemia under normal conditions. It can well simulate the process from leukemia cell involvement to onset, and its research can be closer to clinical indicators.
[0075] Example 2: Treatment of T-ALL using IL-12
[0076] Three days after the non-irradiated leukemia model in Example 1 was constructed, the model mice were randomly divided into two groups, one for the treatment group and the other for the control group. The treatment group was treated with IL-12 (1 μg / mouse / day) intraperitoneally every day, and the control group was injected with PBS. After 7 consecutive days of administration, the treatment was terminated. About 30-40 days later, the mice in the control group developed leukemia and died.
[0077] result:
[0078] After the above treatment, it can be observed that the leukemia process is effectively curbed, and the leukemia mice after modeling can no longer develop leukemia (see Figure 6 The mice that survived the IL-12 treatment showed a very strong ability to resist T-ALL cells. Even if T-ALL cells were transplanted for the second, third, or ten-fold amount, they would not develop T-ALL (see Figure 7 , Figure 8 , Fig. 9 ). Moreover, the overall survival of the surviving mice was close to that of normal mice (see Fig.10 ).
[0079] Example 3: Effects of bone marrow cells from cured mice
[0080] The bone marrow cells of the cured mice in Example 2 were taken, and the bone marrow single cell suspension of the mice cured by IL-12 was prepared according to the conventional method. Specific process: the donor mice were killed by cervical dislocation, soaked in 75% ethanol solution for 1 minute, and the limb bones and ilium of the mice were taken; after removing the muscles, the bone marrow cavity was repeatedly flushed from both ends of the limb bones and ilium with a 1mL syringe, and a single cell suspension was prepared by repeated blowing with a pipette, and the muscle and bone tissue fragments were removed by filtering with a 400-mesh filter membrane and placed on ice for use; after centrifugation (300g×10 minutes), the supernatant was removed and washed once with PBE.
[0081] result:
[0082] The results are as follows Fig.10 As shown. Further statistics on the total survival of cured mice revealed that T-ALL mice treated with IL-12 could continue to survive for about 600 days. It is known that the natural life cycle of C57 BL / 6J mice is only about 1-2 years, and they can survive for 2-3 years under excellent breeding conditions. The results showed that the survival ability of mice was not suppressed after IL-12 treatment.
[0083] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of IL-12 in the preparation of drugs for treating acute T-lymphocytic leukemia.
2. Use of IL-12 in the preparation of drugs for adjuvant treatment of acute T-lymphocytic leukemia.
3. Use of a composition comprising IL-12 in the preparation of a medicament for treating acute T-lymphocytic leukemia.
4. Use of a composition comprising IL-12 in the preparation of a drug for the adjuvant treatment of acute T-lymphocytic leukemia.
5. Use of cells or genetic materials expressing IL-12 in the preparation of drugs for treating acute T-lymphocytic leukemia.
6. Use of cells or genetic materials expressing IL-12 in the preparation of drugs for adjuvant treatment of acute T-lymphocytic leukemia.
7. Use of cells in the preparation of a drug for treating or assisting in the treatment of acute T-lymphocytic leukemia, characterized in that: The cells are bone marrow cells of humans or experimental animals that have been cured by IL-12 treatment.
Citation Information
Patent Citations
Construction method and application of PHF6 <delta> and JAK3<M511I> double-mutation acute T lymphocytic leukemia mouse model
CN113549655A
Mouse acute B lymphocytic leukemia cell strain as well as construction method and application thereof
CN117535244A
method
US20200010560A1
